Boston Scientific Corporation BSX NYSE

Boston Scientific Corporation (BSX) reported strong year-over-year revenue growth of +19.9% through 2025-12 (TTM revenue vs prior-year TTM). Net income showed exceptional earnings expansion of +56.2% YoY, reaching $668M in the latest quarter. The net profit margin is 12.6%, which is moderate. The company has maintained profitability in all 4 quarters. The gross margin is 70.2% (high), up 3.2pp vs the prior year. With a $95B market cap, MOAT composite score of 84/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 35-year annual history, the company was profitable in 24 of 35 years — a mixed long-term record
• INCOME (55/100, Partial) — the company is profitable but margin is below 15%
• MOAT (84/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.